EU Joint Clinical Assessment: First High-Risk Medical Devices Selected Under HTAR
Medical Device Global Market AccessShow Notes
On October 6, 2026, the European Commission selected the first group of high-risk medical devices to undergo a Joint Clinical Assessment (JCA) under the new EU Health Technology Assessment Regulation (HTAR). This episode explains what this pivotal moment means for medical device manufacturers, which device categories are impacted, and how the JCA will reshape the pathway for pricing, reimbursement, and market access across the European Union. We discuss the heightened evidence requirements and provide practical steps for regulatory and market access teams to prepare for this new centralized assessment system.
Key Questions: - What is the EU Joint Clinical Assessment (JCA) and why is it critical for medical device manufacturers? - Which types of high-risk medical devices were part of the first selection on October 6, 2026? - How will the JCA report influence national reimbursement and pricing decisions? - What is the difference between a CE marking submission and a JCA dossier? - What are the new clinical evidence requirements under the Health Technology Assessment Regulation (HTAR)? - How should companies adjust their clinical development strategies for future devices? - What are the immediate actions regulatory teams should take to prepare for a JCA? - When will the HTAR requirements expand to include other Class III and IIb devices?
How Pure Global can help: Pure Global provides comprehensive support for MedTech and IVD companies navigating complex regulatory landscapes like the EU's new HTAR. Our experts develop robust regulatory and market access strategies, ensuring your clinical evidence meets the rigorous demands of Joint Clinical Assessments. We use advanced AI tools to efficiently compile and manage the technical dossiers required for both CE marking and JCA submissions, reducing time-to-market and compliance risks. With a presence in over 30 markets, we act as your local representative and provide continuous monitoring to keep you ahead of regulatory changes. Contact us at [email protected], visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai to accelerate your global growth.
More from Medical Device Global Market Access
Australia's Therapeutic Goods Administration (TGA) has updated its guidance on fee reductions for medical device conformity and ARTG application audits. Effective October 1, 2026, these changes introduce a new fee model for design examinations based on Unique Product Identifier (UPI) components, increase certain recertification fees, and raise the minimum fee for subsequent devices in mandatory audits. This episode details what these changes mean for manufacturers and how to prepare your regulatory strategy and budget.
Australia's Therapeutic Goods Administration (TGA) has clarified that many AI-powered digital scribes are considered medical devices, not simple administrative tools. Following a review published on October 16, 2023, the TGA found that 8 of 12 reviewed products were likely unapproved medical devices. This episode breaks down the TGA's reasoning, focusing on how a software's intended purpose—such as summarizing or analyzing clinical information—triggers regulatory oversight. We discuss the immediate compliance obligations for manufacturers and provide practical steps for developers of Software as a Medical Device (SaMD) to navigate this evolving regulatory landscape.
On October 14, 2026, Japan's PMDA published its draft guidance, 'Review Points for Medical Devices Utilizing Generative AI.' This episode explores the key safety and performance evaluation criteria that manufacturers must understand to successfully bring advanced AI-enabled medical devices to the Japanese market. We cover the PMDA's expectations for data quality, AI model lifecycle management, transparency, and risk management, providing practical steps for regulatory and quality teams to prepare for these new requirements.
Health Canada has released revised guidance on its framework for exceptional importation and sale of medical devices, effective October 16, 2026. This episode details the key clarifications for manufacturers facing potential device shortages, outlines the updated application requirements and responsibilities for importers, and highlights the upcoming stakeholder information session on October 21, 2026. We provide practical steps for regulatory and quality teams to adapt to these changes and leverage the framework as part of a robust supply chain strategy.
On October 9, 2026, the US FDA issued new draft guidance clarifying premarket submission requirements for robotically assisted surgical (RAS) devices. This episode breaks down the FDA's key recommendations for non-clinical testing, clinical evidence, software validation, cybersecurity, human factors, and labeling. We provide practical steps for manufacturers to align their 510(k), De Novo, or PMA submissions with the agency's current expectations to ensure a smoother path to market access.